Lynparza (olaparib)

LYNPARZA® is geïndiceerd voor 4 therapeutische indicaties. Klik op de icoontjes voor meer informatie.


Hulpbronnen en materialen

Klinische studies

Prof. Denys presenteert de resultaten van de OlympiAD trial

Prof. Denys beantwoordt enkele vragen betreffende gBRCA testing en behandeling van gemetastaseerde TNBC patiënten

MoA en onderzoek naar genetische mutaties





Onderzoek naar genetische mutaties

Voor patiënten

Binnenkort beschikbaar

Dagboek voor Lynparza patiënten


Momenteel zijn er geen evenementen.


  1. LYNPARZA® 100 mg and 150 mg tabletten, samenvatting van de productkenmerken, meest recente versie
  2. (bezocht 25/10/2021)
  3. Weston VJ et al. The PARP inhibitor olaparib induces signicant killing of ATM-decient lymphoid tumour cells in vitro and in vivo. Blood. 2010;116(22):4578–4587.
  4. Weil MK and Chen AP. PARP inhibitor treatment in ovarian and breast cancer. Curr Probl Cancer. 2011;35(1):7–50.
  5. Aly A and Ganesan S. BRCA1, PARP, and 53BP1: Conditional synthetic lethality and synthetic viability. J Mol Cell Biol. 2011;3(1):66–74.
  6. Robson M et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med. 2017;377(6):523–533.
  7. Robson M et al. OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Ann Oncol. 2019;30(4):558–566.
  8. Robson M et al. Patient-reported outcomes in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer receiving olaparib versus chemotherapy in the OlympiAD trial. Eur J Cancer. 2019;120:20–30.
  9. Cardoso F et al. 4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC4). Ann Oncol. 2018;29(8):1634–1657.
  10. Winter C et al. Targeted sequencing of BRCA1 and BRCA2 across a large unselected breast cancer cohort suggests that one-third of mutations are somatic [supplementary data]. Ann Oncol. 2016;27(8):1532–1538.